Bioline Rx Ltd - ADR
BLRX
Get informed when a big investor buys or sells
+ FollowMarket Cap$8.93M
Close$
$-2.46
222.2% downside
Current Fair Value
222.2% downsideOvervalued by 222.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $8.93 Million |
|---|---|
| Enterprise Value | $12.24 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.29 |
| Beta | 0.7 |
| Outstanding Shares | 4,441,345 |
Return
| Return on Equity | -111.99% |
|---|---|
| Return on Assets | -46.06% |
| Return on Invested Capital | -48.67% |
Valuation & Multiples
| P/E Ratio | -1.27 |
|---|---|
| PEG | 5.78 |
| Price to Sales | 2.01 |
| Price to Book Ratio | 0.67 |
| Enterprise Value to Revenue | 2.03 |
| Enterprise Value to EBIT | -1.27 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.65 |
| Debt to Equity | 0.58 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.15
Average shareholder expectationRevenue Estimate
$500,000
Average shareholder expectationNext Earnings Call
Expected Date
November 18, 2026
EPS Estimate
$-0.09
Average shareholder expectationRevenue Estimate
$375,000
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 39,000▲ 282.35% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.50%▲ 1.06% |
|---|---|
| Total Invested | $207,718▲ 359.31% |
| Investors Holding | 15▲ 2.00% |
ESG Score
No data
About Bioline Rx Ltd
22 employees
CEO: Philip Serlin BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial f...